Clinical impact

Clinical impact

Sensitivity

Different cancers shed DNA into the bloodstream at different rates.8 The proportion of tumor-derived cfDNA in the blood tends to increase as cancer progresses. Cancers that shed more DNA at earlier stages tend to be associated with higher mortality.9 The greater the proportion of cfDNA in a sample, the stronger its signal and the more likely it is to be detected by the Galleri test.5 The cancer types specified here account for 63% of all estimated cancer deaths.6,7 The Galleri test detected a cancer signal in approximately 3 out of 4 people with one of the cancers in this high-signal cancer group.1

How can we assist?

If you have questions or would like to know more,
contact us or see our FAQs.

Sign up for more information
about the Galleri test

  1. *The Galleri test is intended to detect a cancer signal and predict cancer signal origin to inform diagnostic evaluation.

    Cancer cases enrolled in CCGA Study1 were assigned a​“cancer type” as defined in the American Joint Committee on Cancer (AJCC) manual (8th edition)2 (For this list of Cancer types detected, some of the names were modified/​edited to organize for easy reference). Cancer signals were detected across more than 50 AJCC-cancer types, which supports the potential for the Galleri test to detect a cancer signal over a diverse range of cancers across a wide biologic spectrum.